Harboe M et al. Properdin binding to complement activating surfaces depends on initial C3b deposition. PNAS, 2017, Early Edition DOI: 10.1073/pnas.1612385114
Ekdahl KN et al. The innate immunity response: A key factor in biocompatibility. In Woodhead publishing series in biomaterials: Number 120 "Bioresorbable polymers for biomedical applications. From fundamentals to translational medicine”. Eds: Perale G, Hilborn J. Elsevier. 2017, pp 85-94.
Mastellos DC et al. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 2016, 221, 10, p 1046-1057 http://dx.doi.org/10.1016/j.imbio.2016.06.013
Hajishengallis G et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Seminars in Immunology, 2016, 28, 3, p 285–291 http://dx.doi.org/10.1016/j.smim.2016.03.006
Evgin L et al. Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy - Oncolytics 2016, 3, Article 16027, http://dx.doi.org/10.1038/mto.2016.27
Hajishengallis G et al. More than complementing Tolls: complement–Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunological Reviews 2016, 274, 1, p 233–244 DOI:10.1111/imr.12467
Ricklin D et al. Complement component C3 – The "Swiss Army Knife” of innate immunity and host defense. Immunological Reviews 2016, 274, 1, p 33-58 DOI: 10.1111/imr.12500
Schmidt CQ et al. Protection of host cells by complement regulators. Immunological Reviews 2016, 274, 1, p 152–171 DOI: 10.1111/imr.12475
Abicht J-M et al. Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood. Xenotransplantation 2016, Published online DOI: 10.1111/xen.12262
Lindorfer MA et al. Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical Immunology, 2016, 171, p 32–35 http://dx.doi.org/10.1016/j.clim.2016.08.017
Ricklin D et al. New milestones ahead in complement-targeted therapy. Seminars in Immunology, 2016, 28, 3, p 208–222 http://dx.doi.org/10.1016/j.smim.2016.06.001
Ricklin D et al. Complement in disease: a defence system turning offensive. Nature Reviews Nephrology 2016, 12, p. 383–401 doi:10.1038/nrneph.2016.70
Broders-Bondon F et al. Control of the collective migration of enteric neural crest cells by the Complement anaphylatoxin C3a and N-cadherin. Developmental Biology, 2016, 414, Issue 1, p 85-99 http://dx.doi.org/10.1016/j.ydbio.2016.03.022
Forneris F et al. Regulators of complement activity mediate inhibitory mechanisms through a common C3b‐binding mode. The EMBO Journal 2016, 35, p 1133-1149 DOI 10.15252/embj.201593673
Schmidt CQ et al. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology, 2016, 221, 4, p 503–511 http://dx.doi.org/10.1016/j.imbio.2015.12.009
Maekawa T et al. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. Clin Periodont 2016, 43, 3, p 238–249 DOI:10.1111/jcpe.12507
Harder MJ et al. Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H–like Protein 1 Reveal Functional Determinants of Complement Regulation J Immunol 2016, 196 (2) 866-876 DOI: https://doi.org/10.4049/jimmunol.1501919
Wang J et al. Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clinical Immunology 2016, 162, p 37–44 http://dx.doi.org/10.1016/j.clim.2015.11.002
Mastellos DC et al. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Molecular Oral Microbiology, 2016, 31, 1, p 3–17 DOI: 10.1111/omi.12129
Ricklin D et al. Therapeutic control of complement activation at the level of the central component C3. Immunobiology, 221, 6, 2016, p 740–746 http://dx.doi.org/10.1016/j.imbio.2015.06.012
Pallavi S et al. Regulation of tissue infiltration by neutrophils: role of integrin [alpha]3[beta]1 and other factors. Current Opinion in Hematology 23(1), 2016, p 36–43 DOI: 10.1097/MOH.0000000000000198
Ekdahl KN et al. Complement inhibition in biomaterial- and biosurface-induced thromboinflammation. Seminars in Immunology, 2016; 28(3); 268-277 http://dx.doi.org/10.1016/j.smim.2016.04.006
Teramura Y et al. A hybrid of cells and pancreatic islets toward a new bioartificial pancreas. Regenerative Therapy 2016 in press
Teramura Y et al. Cell adhesion induced using surface modification with cell-penetrating peptide-conjugated PEG-lipid: A new cell glue for 3D cell-based structures. ACS Appl Mater Interfaces. 2016 (E-pub ahead of print Dec 15) PMID: 27976850
Ekdahl KN et al.
Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation. Immunol Rev. 2016 Nov;274(1):245-269 doi:10.1111/imr.12471
Gustafson E et al.
Control of IBMIR induced by fresh and cryopreserved hepatocytes by low molecular weight dextran sulfate versus heparin. Cell Transplant 2016 (E-pub ahead of print Jul 22) PMID: 27452808
Kozarcanin H et al.
The lectin complement pathway serine proteases (MASPs) represent a crossroad between activation of the coagulation and complement systems in thrombotic disease. Thrombosis Haemostasis 2016 14(3):531-545 doi: 10.1111/jth.1320
Niyonzima N et al.
Complement activation by cholesterol crystals triggers a subsequent cytokine response. Mol Immunol 2016 (E-pub ahead of print Sept 28, 2016). doi: 10.1016/j.molimm.2016.09.019
Otterdal K et al.
Rickettsia conorii is a potent complement activator in vivo and combined inhibition of complement and CD14 is required for attenuation of the cytokine response ex vivo. Clin Microbiol Infec 22:734.e1-6. 2016. doi: 10.1016/j.cmi.2016.05.010
Otterdal K et al. High serum CXCL10 in Rickettsia conorii infection is endothelial cell mediated subsequent to whole blood activation. Cytokine 83:269-274. 2016.
Landsem A et al.
C1-inhibitor efficiently delays clot development in normal human whole blood and inhibits Escherichia coli-induced coagulation measured by thromboelastometry. Thromb Res 143:63-70. 2016. doi: 10.1016/j.thromres.2016.04.024
Barratt-Due A et al.
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology 55:1337-1339. 2016. doi: 10.1093/rheumatology/kew040
Seip KF et al.
Exhaled nitric oxide, complement activation and cytokine production in pigs infused with bradykinin. J Cardiol Clin Res 36: 517-573. 2016. doi: 10.1097/SHK.0b013e3182336a34
Gustavsen A et al.
Combined inhibition of complement and CD14 attenuates bacteria-induced inflammation in human whole blood more efficiently than antagonizing TLR4-MD2. J Infect Dis 214: 140-150. 2016. doi: 10.1093/infdis/jiw100
Ørning P et al. Alginate microsphere compositions dictate different mechanisms of complement activation with consequences for cytokine release and leukocyte activation. J Control Release 229:58-69. 2016.
Pilely K et al. Cholesterol crystals activate the lectin complement pathway via ficolin-2 and MBL - implications for the progression of atherosclerosis. J Immunol 196:5064-5074. 2016.
Kourtzelis I et al.
Developmental endothelial locus-1 modulates platelet-monocyte interactions and instant blood-mediated inflammatory reaction in islet transplantation. Thromb Haemost. http://dx.doi.org/10.1160/TH15-05-0429
Asif S et al.
Heparinization of cell surfaces with short peptide-conjugated PEG-lipid regulates thromboinflammation in transplantation of human MSCs and hepatocytes. Acta Biomater DOI: 10.1016/j.actbio.2016.02.018
Duehrkop C et al.
Development and characterization of an innovative heparin coating to stabilize and protect liposomes against adverse immune reactions. Colloids Surf B Biointerfaces DOI: 10.1016/j.colsurfb.2016.02.014
Nymo S et al.
Human endothelial cell activation by Escherichia coli and Staphylococcus aureus is mediated by TNF and IL-1β secondarily to activation of C5 and CD14 in whole blood. J Immunol 126:2293-2299. 2015. doi: 10.4049/jimmunol.1502220
Aresvik DM et al.
Increased levels of interferon-inducible protein 10 (IP-10) in 22q11.2 Deletion Syndrome. Scand J Immunol 83:188-194. 2015. doi: 10.1111/sji.12406
Stylianou E et al.
Specific Allergen Immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis. Scand J Clin Lab Invest 76:118-127. 2015. doi: 10.3109/00365513.2015.1110856
Skjeflo EW et al.
Combined inhibition of complement and CD14 improved outcome in porcine polymicrobial sepsis. Crit Care 19:415 (1-8). 2015. doi: 10.1186/s13054-015-1129-9
Fretland AA et al.
Inflammatory response after laparoscopic versus open resection of colorectal liver metastasis. Medicine 94:e1786. 2015. doi: 10.1097/MD.0000000000001786
<!- -EndFragment- ->
Volokhina EB et al.
Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 160:237-243. 2015. doi: 10.1016/j.clim.2015.05.018
Hamad OA et al.
Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18. Thromb Haemost DOI: 10.1160/TH15-02-0162
Silasi-Mansat R et al.
Complement inhibition decreases early fibrogenic events in the lung of septic baboons. Journal of Cellular and Molecular Medicine DOI: 10.1111/jcmm.12667
Nordling et al.
Vascular repair utilising immobilised heparin conjugate for protection against early activation of inflammation and coagulation.Thrombosis and Haemostasis http://dx.doi.org/10.1160/TH14-09-0724
Ekstrand-Hammarström B et al.
TiO2 nanoparticles tested in a novel screening whole human blood model of toxicity trigger adverse activation of the kallikrein system at low concentrations. Biomaterials doi:10.1016/j.biomaterials.2015.01.031
Engberg A et al.
Prediction of inflammatory responses induced by biomaterials in contact with human blood using protein fingerprint from plasma. Biomaterials 10.1016/j.biomaterials.2014.09.011
Huang S et al.
Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. NDT Plus 10.1093/ckj/sfu127
Bruun Wyller et al.
Plasma cytokine expression in adolescent chronic fatigue syndrome. Brain, Behavior, and Immunity 10.1016/j.bbi.2014.12.025
Reis et al.
Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 10.1016/j.imbio.2014.10.026
Kourtzelis I et al.
Complement Inhibition in a Xenogeneic Model of Interactions Between Human Whole Blood and Porcine Endothelium. Hormone and Metabolic Research 10.1055/s-0034-1390452
Sfyroera G et al.
Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. Journal of Immunology 10.4049/jimmunol.1402781
Mastellos DC et al.
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation 10.1111/eci.12419
Mitroulis I et al.
Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacology and Therapeutics 10.1016/j.pharmthera.2014.11.008
Egge KH et al.
Organ inflammation in porcine Escherichia coli sepsis is markedly attenuated by combined inhibition of C5 and CD14. Immunobiology 10.1016/j.imbio.2015.04.002
Hallstensen RF et al.
Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 10.1016/j.imbio.2014.11.003
Kotimaa JP et al.
Functional assessment of mouse complement pathway activities and quantification of C3b/C3c/iC3b in an experimental model of mouse renal ischaemia/reperfusion injury. Journal of Immunological Methods 10.1016/j.jim.2015.02.010
Kotimaa JP et al.
Functional assessment of rat complement pathway activities and quantification of soluble C5b-9 in an experimental model of renal ischemia/reperfusion injury. Immunological Methods 10.1016/j.jim.2014.06.011
Egge KH et al.
The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load. Clinical and Experimental Immunology 10.1111/cei.12645
Berg A et al.
Complement Activation Correlates With Disease Severity and Contributes to Cytokine Responses in Plasmodium falciparum Malaria. Journal of Infectious Diseases 10.1093/infdis/jiv283
Volokhina EB et al.
Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology 10.1016/j.clim.2015.05.018
Landsem A et al.
The key roles of complement and tissue factor in Escherichia coli -induced coagulation in human whole blood. Clinical and Experimental Immunology 10.1111/cei.12663
Rafail S et al.
Complement Deficiency Promotes Cutaneous Wound Healing in Mice. Journal of Immunology 10.4049/jimmunol.1402354
Evgin L et al.
Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques. Molecular Therapy 10.1038/mt.2015.49
Zhang Y et al.
Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 10.1016/j.imbio.2015.04.001
Rosengren-Holmberg JP et al.
Heparin molecularly imprinted surfaces for the attenuation of complement activation in blood. Biomaterials Science 10.1039/c5bm00047e
Nordling S et al.
A Novel In vitro Model for Studying the Interactions Between Human Whole Blood and Endothelium. Journal of Visualized Experiments 10.3791/52112
Nilsson B et al.
The role and regulation of complement activation as part of the thromboinflammation elicited in cell therapies. Molecular Immunology doi:10.1016/j.molimm.2014.06.009
Huang Y et al.
Conjugation to Albumin-Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. ChemMedChem 10.1002/cmdc.201402212
Risitano AM et al.
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 10.1182/blood-2013-11-536573
Mastellos DC et al.
Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology 10.1586/17474086.2014.953926
Maekawa T et al.
Genetic and Intervention Studies Implicating Complement C3 as a Major Target for the Treatment of Periodontitis. Journal of Immunology 10.4049/jimmunol.1400569
Maekawa T et al.
Porphyromonas gingivalis Manipulates Complement and TLR Signaling to Uncouple Bacterial Clearance from Inflammation and Promote Dysbiosis. Cell Host and Microbe 10.1016/j.chom.2014.05.012
Hajishengallis A et al.
Neutrophil homeostasis and inflammation: novel paradigms from studying periodontitis. Journal of Leukocyte Biology 10.1189/jlb.3VMR1014-468R